2025-09-29
Turning Space Into a Living Laboratory
Molly Mulligan on Bioprinting, Pharmaceutical Innovation, and the Expansion of Space-Based Research
Molly Mulligan, Director of Business Development at Redwire Space, has dedicated over a decade to advancing the intersection of biology, engineering, and space science. Her professional trajectory—spanning the development of biological payloads for nanosatellites to pioneering regenerative medicine research in orbit—illustrates the increasing role of commercial entities in shaping the future of space exploration.
Today, Mulligan is at the forefront of efforts to position low Earth orbit (LEO) as a new class of laboratory where gravity itself becomes an adjustable variable, opening unprecedented opportunities for innovation across life sciences, pharmaceuticals, and beyond.
Space as a Scientific Laboratory
“Space is often perceived as inaccessible and remote. In practice, however, it should be understood as another type of laboratory.' — Molly Mulligan
While terrestrial laboratories allow researchers to alter variables such as temperature and pressure, gravity remains a fixed constant. Space research fundamentally alters this paradigm. Through the use of centrifuges aboard the International Space Station (ISS), scientists can replicate lunar, Martian, or terrestrial gravity conditions, enabling direct comparative research.
This unique capability provides critical insights into:
- Life Sciences: Understanding cell and tissue behavior in the absence of gravitational sedimentation.
- Pharmaceutical Development: Producing drug crystals with fewer defects, enhancing both quality and manufacturability.
- Regenerative Medicine: Advancing tissue engineering and bioprinting technologies under conditions not achievable on Earth.
“By treating gravity as a variable, researchers gain new perspectives on both physical and biological systems—perspectives that cannot be realized under terrestrial constraints.”
Pharmaceutical Discovery and Bioprinting in Orbit
Among the most promising applications of space-based research is pharmaceutical innovation. Microgravity enables the crystallization of larger, more uniform drug compounds, thereby advancing manufacturing processes and therapeutic efficacy on Earth.
Equally significant is the progress in regenerative medicine. At Redwire, Mulligan and her colleagues are pioneering 3D bioprinting in microgravity—a domain that offers possibilities unattainable under Earth conditions.
“On Earth, biological inks must be artificially thickened or crosslinked to maintain structural integrity. In microgravity, we are able to use inks with the viscosity of water. This allows us to conduct biology for its own sake. Cells remain suspended, tissues maintain form, and we can condition and strengthen them prior to their return to Earth.”
This advancement marks a decisive step toward the long-term goal of developing functional tissues and, ultimately, organ replacement technologies.
The Contribution of Humans In Space
Mulligan also highlights the importance of initiatives such as the Humans In Space (HIS) Challenge, in which she served as a judge in 2024.
“The barriers to entry for space research remain significant. Launch delays, extended timelines, and long-term return on investment can discourage new entrants. The Humans In Space Challenge provides a critical platform for innovators and startups, enabling them to engage with an industry that is otherwise difficult to access.”
By lowering these barriers, HIS supports the integration of health technology and space research, creating new pathways for innovation with tangible benefits on Earth.
Building a Collaborative Research Ecosystem
For Mulligan, the value of space-based research extends well beyond the astronaut corps. Discoveries made in orbit—whether through pharmaceutical crystallization, bioprinting, or other disciplines—ultimately accelerate healthcare advancements on Earth.
“Space research is not only about enabling exploration. It is about catalyzing discovery, accelerating development, and delivering meaningful outcomes for humanity.”
Looking Forward
As commercial space infrastructure expands, organizations such as Redwire and initiatives like Humans In Space are establishing the foundations of a global research ecosystem. In this model, LEO becomes not only a destination but also a catalyst for innovation with direct societal benefit.
Humans In Space remains committed to convening researchers, entrepreneurs, and international partners to advance healthcare innovation in orbit and on Earth. The work of leaders such as Molly Mulligan underscores the transformative potential of this endeavor.